Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Arver

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Molecular Psychiatry|December 9, 2015
Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in SwedenK Kosidou, C Dalman, L Widman, et al.
Cancer|July 1, 1994
Multiple neuropeptide immunoreactivities in a renin-producing human paragangliomaG Fried, L M Wikström, A Höög, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal menA S Dobs, A W Meikle, S Arver, et al.
The Journal of Urology|May 1, 1996
Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal systemS Arver, A S Dobs, A W Meikle, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Androgen replacement in the treatment of Klinefelter's syndrome: efficacy and safety of a nonscrotal permeation-enhanced testosterone transdermal systemA W Meikle, A S Dobs, S Arver, et al.
Clinical Endocrinology|March 14, 1998
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal menS Arver, A S Dobs, A W Meikle, et al.
Andrology|February 13, 2014
Inhibin B concentration is predictive for long-term azoospermia in men treated for testicular cancerS Isaksson, J Eberhard, O Ståhl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2019
Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatmentK Weibring, C Nord, O Ståhl, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2001
Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal systemA S Dobs, P S Bachorik, S Arver, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 1998
Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levelsS Bhasin, T W Storer, N Asbel-Sethi, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Molecular Psychiatry|December 9, 2015
Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in SwedenK Kosidou, C Dalman, L Widman, et al.
Cancer|July 1, 1994
Multiple neuropeptide immunoreactivities in a renin-producing human paragangliomaG Fried, L M Wikström, A Höög, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal menA S Dobs, A W Meikle, S Arver, et al.
The Journal of Urology|May 1, 1996
Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal systemS Arver, A S Dobs, A W Meikle, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Androgen replacement in the treatment of Klinefelter's syndrome: efficacy and safety of a nonscrotal permeation-enhanced testosterone transdermal systemA W Meikle, A S Dobs, S Arver, et al.
Clinical Endocrinology|March 14, 1998
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal menS Arver, A S Dobs, A W Meikle, et al.
Andrology|February 13, 2014
Inhibin B concentration is predictive for long-term azoospermia in men treated for testicular cancerS Isaksson, J Eberhard, O Ståhl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2019
Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatmentK Weibring, C Nord, O Ståhl, et al.
The Journal of Clinical Endocrinology and Metabolism|March 10, 2001
Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal systemA S Dobs, P S Bachorik, S Arver, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 1998
Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levelsS Bhasin, T W Storer, N Asbel-Sethi, et al.
Pageof 6